| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 59 | 2025 | 866 | 7.960 |
Why?
|
| Pancreatic Neoplasms | 43 | 2026 | 928 | 4.750 |
Why?
|
| Antineoplastic Agents | 62 | 2024 | 2214 | 4.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2026 | 1963 | 4.270 |
Why?
|
| Adenocarcinoma | 22 | 2026 | 925 | 2.990 |
Why?
|
| Neoplasms | 43 | 2022 | 2906 | 2.510 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2020 | 981 | 2.220 |
Why?
|
| Amyloid Precursor Protein Secretases | 7 | 2021 | 78 | 2.010 |
Why?
|
| Xenograft Model Antitumor Assays | 35 | 2025 | 934 | 2.010 |
Why?
|
| Deoxycytidine | 19 | 2025 | 220 | 2.000 |
Why?
|
| Camptothecin | 19 | 2025 | 138 | 1.920 |
Why?
|
| Antibodies, Monoclonal, Humanized | 29 | 2025 | 992 | 1.820 |
Why?
|
| Liver Neoplasms | 11 | 2025 | 776 | 1.770 |
Why?
|
| Immunoconjugates | 12 | 2021 | 138 | 1.710 |
Why?
|
| Carcinoma, Pancreatic Ductal | 11 | 2025 | 293 | 1.530 |
Why?
|
| Antibodies, Monoclonal | 21 | 2024 | 1505 | 1.430 |
Why?
|
| Colonic Neoplasms | 10 | 2024 | 257 | 1.380 |
Why?
|
| Quinazolines | 11 | 2015 | 266 | 1.380 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2025 | 881 | 1.340 |
Why?
|
| Tetrahydronaphthalenes | 3 | 2017 | 31 | 1.330 |
Why?
|
| Valine | 3 | 2017 | 83 | 1.300 |
Why?
|
| ErbB Receptors | 14 | 2016 | 635 | 1.280 |
Why?
|
| src-Family Kinases | 4 | 2017 | 92 | 1.260 |
Why?
|
| Molecular Targeted Therapy | 11 | 2024 | 439 | 1.180 |
Why?
|
| ras Proteins | 10 | 2017 | 150 | 1.170 |
Why?
|
| Fluorouracil | 15 | 2025 | 231 | 1.120 |
Why?
|
| Maximum Tolerated Dose | 22 | 2022 | 210 | 1.110 |
Why?
|
| Rectal Neoplasms | 8 | 2024 | 159 | 1.070 |
Why?
|
| Enzyme Inhibitors | 9 | 2020 | 820 | 1.050 |
Why?
|
| Benzodioxoles | 5 | 2012 | 161 | 1.050 |
Why?
|
| Cetuximab | 11 | 2025 | 111 | 1.030 |
Why?
|
| Humans | 204 | 2026 | 145475 | 1.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2018 | 382 | 1.000 |
Why?
|
| Mutation | 15 | 2021 | 4075 | 0.970 |
Why?
|
| Bevacizumab | 8 | 2024 | 168 | 0.970 |
Why?
|
| CD47 Antigen | 1 | 2025 | 42 | 0.910 |
Why?
|
| Pyridines | 9 | 2022 | 609 | 0.900 |
Why?
|
| Aged | 81 | 2026 | 26153 | 0.900 |
Why?
|
| Biomarkers, Tumor | 13 | 2024 | 1321 | 0.880 |
Why?
|
| Cell Line, Tumor | 33 | 2025 | 3542 | 0.870 |
Why?
|
| Wnt Signaling Pathway | 8 | 2024 | 211 | 0.870 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2018 | 624 | 0.860 |
Why?
|
| Benzimidazoles | 7 | 2024 | 189 | 0.850 |
Why?
|
| Neoadjuvant Therapy | 13 | 2026 | 465 | 0.830 |
Why?
|
| Middle Aged | 87 | 2026 | 36215 | 0.820 |
Why?
|
| Anilides | 3 | 2022 | 84 | 0.820 |
Why?
|
| Receptor, Notch1 | 3 | 2015 | 63 | 0.820 |
Why?
|
| Aldehyde Dehydrogenase | 6 | 2017 | 99 | 0.810 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 133 | 0.780 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 31 | 0.770 |
Why?
|
| Signal Transduction | 22 | 2019 | 5216 | 0.760 |
Why?
|
| Mice, Nude | 24 | 2024 | 679 | 0.760 |
Why?
|
| Aniline Compounds | 4 | 2011 | 120 | 0.750 |
Why?
|
| Immunotherapy | 5 | 2022 | 666 | 0.730 |
Why?
|
| Medical Oncology | 9 | 2025 | 339 | 0.730 |
Why?
|
| Female | 112 | 2026 | 78845 | 0.710 |
Why?
|
| Quinolines | 4 | 2022 | 190 | 0.700 |
Why?
|
| Treatment Outcome | 43 | 2026 | 11772 | 0.680 |
Why?
|
| Nitriles | 3 | 2011 | 207 | 0.660 |
Why?
|
| Paclitaxel | 9 | 2025 | 257 | 0.660 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2017 | 2028 | 0.650 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 73 | 0.650 |
Why?
|
| Neoplasm Metastasis | 16 | 2025 | 688 | 0.640 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 552 | 0.640 |
Why?
|
| Drug Design | 6 | 2022 | 175 | 0.630 |
Why?
|
| Mice | 44 | 2025 | 18329 | 0.630 |
Why?
|
| Carcinoma | 3 | 2011 | 225 | 0.620 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 198 | 0.610 |
Why?
|
| Sulfones | 4 | 2015 | 127 | 0.610 |
Why?
|
| Gene Dosage | 3 | 2015 | 145 | 0.600 |
Why?
|
| Animals | 58 | 2025 | 38030 | 0.600 |
Why?
|
| Dasatinib | 2 | 2017 | 58 | 0.600 |
Why?
|
| Administration, Oral | 14 | 2017 | 866 | 0.600 |
Why?
|
| Pancreatectomy | 4 | 2026 | 289 | 0.600 |
Why?
|
| Adult | 69 | 2025 | 40777 | 0.590 |
Why?
|
| Glycine | 4 | 2015 | 186 | 0.590 |
Why?
|
| Neoplasm Staging | 17 | 2024 | 1471 | 0.590 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 242 | 0.570 |
Why?
|
| Male | 86 | 2026 | 72843 | 0.570 |
Why?
|
| Aged, 80 and over | 32 | 2025 | 8333 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1581 | 0.570 |
Why?
|
| Pyrimidinones | 4 | 2015 | 125 | 0.560 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2015 | 70 | 0.560 |
Why?
|
| Receptors, Notch | 3 | 2015 | 90 | 0.560 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 734 | 0.560 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.540 |
Why?
|
| Pyrimidines | 7 | 2022 | 530 | 0.530 |
Why?
|
| Pyridones | 4 | 2015 | 209 | 0.520 |
Why?
|
| Liver Transplantation | 1 | 2025 | 826 | 0.520 |
Why?
|
| Albumins | 6 | 2025 | 119 | 0.500 |
Why?
|
| Phenylurea Compounds | 7 | 2022 | 119 | 0.500 |
Why?
|
| DNA Helicases | 3 | 2024 | 136 | 0.500 |
Why?
|
| Benzazepines | 2 | 2014 | 35 | 0.500 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2015 | 70 | 0.480 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 4560 | 0.480 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 271 | 0.480 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2025 | 666 | 0.470 |
Why?
|
| Autophagy | 1 | 2018 | 291 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 238 | 0.460 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2012 | 28 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 641 | 0.460 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2021 | 41 | 0.450 |
Why?
|
| Apoptosis | 14 | 2022 | 2440 | 0.450 |
Why?
|
| Microsatellite Instability | 5 | 2025 | 55 | 0.450 |
Why?
|
| Drug Administration Schedule | 14 | 2017 | 782 | 0.450 |
Why?
|
| Patient Rights | 1 | 2015 | 11 | 0.440 |
Why?
|
| Disease-Free Survival | 11 | 2023 | 767 | 0.440 |
Why?
|
| Cell Proliferation | 18 | 2024 | 2507 | 0.440 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 24 | 0.440 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 18 | 0.440 |
Why?
|
| Combined Modality Therapy | 8 | 2024 | 1266 | 0.430 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 149 | 0.430 |
Why?
|
| Leucovorin | 9 | 2025 | 98 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2026 | 423 | 0.420 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 184 | 0.420 |
Why?
|
| DNA-Binding Proteins | 5 | 2024 | 1480 | 0.410 |
Why?
|
| Azepines | 3 | 2020 | 105 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 288 | 0.380 |
Why?
|
| Prognosis | 10 | 2023 | 4316 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2021 | 219 | 0.370 |
Why?
|
| Methylurea Compounds | 3 | 2006 | 7 | 0.370 |
Why?
|
| Neutropenia | 7 | 2022 | 154 | 0.360 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 10 | 2019 | 254 | 0.360 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 108 | 0.340 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2019 | 218 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 5 | 2018 | 181 | 0.330 |
Why?
|
| Terminal Care | 1 | 2015 | 283 | 0.330 |
Why?
|
| Anus Neoplasms | 2 | 2023 | 32 | 0.330 |
Why?
|
| Gamma Rays | 2 | 2021 | 57 | 0.320 |
Why?
|
| Survival Rate | 9 | 2025 | 2090 | 0.320 |
Why?
|
| Area Under Curve | 9 | 2018 | 331 | 0.320 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 13 | 0.310 |
Why?
|
| Genes, ras | 2 | 2018 | 96 | 0.310 |
Why?
|
| Faculty, Medical | 2 | 2025 | 303 | 0.300 |
Why?
|
| Drug Synergism | 2 | 2024 | 354 | 0.300 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 454 | 0.300 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 137 | 0.300 |
Why?
|
| Phthalazines | 2 | 2023 | 63 | 0.300 |
Why?
|
| Immunoblotting | 6 | 2015 | 295 | 0.290 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 191 | 0.280 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1716 | 0.270 |
Why?
|
| Cell Cycle Proteins | 5 | 2018 | 630 | 0.270 |
Why?
|
| Metabolic Clearance Rate | 6 | 2012 | 115 | 0.260 |
Why?
|
| Sirolimus | 4 | 2012 | 280 | 0.260 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2019 | 24 | 0.260 |
Why?
|
| Organoplatinum Compounds | 6 | 2014 | 65 | 0.260 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 265 | 0.250 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2018 | 67 | 0.250 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 1061 | 0.250 |
Why?
|
| Membrane Proteins | 6 | 2021 | 1164 | 0.250 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 231 | 0.250 |
Why?
|
| Pyrazoles | 4 | 2022 | 517 | 0.250 |
Why?
|
| Genetic Testing | 1 | 2009 | 480 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1149 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 3 | 2018 | 286 | 0.240 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 1101 | 0.240 |
Why?
|
| Diarrhea | 2 | 2026 | 193 | 0.240 |
Why?
|
| Capecitabine | 4 | 2015 | 56 | 0.240 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2026 | 28 | 0.240 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2022 | 223 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 86 | 0.230 |
Why?
|
| Chemoembolization, Therapeutic | 3 | 2013 | 89 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 1443 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 561 | 0.230 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2025 | 14 | 0.230 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2664 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 440 | 0.220 |
Why?
|
| Heterografts | 3 | 2021 | 143 | 0.220 |
Why?
|
| Survival Analysis | 7 | 2017 | 1374 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 2 | 2025 | 1261 | 0.220 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 441 | 0.220 |
Why?
|
| Cyclosporine | 2 | 2018 | 256 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 409 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 1189 | 0.210 |
Why?
|
| Drug Discovery | 3 | 2016 | 153 | 0.210 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 307 | 0.210 |
Why?
|
| Collagen Type I | 1 | 2025 | 143 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5423 | 0.210 |
Why?
|
| Sulfonamides | 4 | 2022 | 583 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2016 | 372 | 0.210 |
Why?
|
| Retrospective Studies | 14 | 2026 | 17291 | 0.210 |
Why?
|
| cdc25 Phosphatases | 1 | 2024 | 13 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2015 | 749 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 124 | 0.200 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2015 | 72 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2018 | 899 | 0.200 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 343 | 0.200 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 206 | 0.200 |
Why?
|
| Oncologists | 1 | 2024 | 47 | 0.200 |
Why?
|
| DNA Mismatch Repair | 3 | 2021 | 53 | 0.200 |
Why?
|
| Subacute Care | 1 | 2024 | 84 | 0.190 |
Why?
|
| Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
|
| TCF Transcription Factors | 2 | 2020 | 19 | 0.190 |
Why?
|
| Colon | 1 | 2005 | 309 | 0.190 |
Why?
|
| DNA | 1 | 2009 | 1435 | 0.190 |
Why?
|
| Perioperative Care | 1 | 2025 | 231 | 0.190 |
Why?
|
| DNA Mutational Analysis | 5 | 2012 | 407 | 0.190 |
Why?
|
| Collagen | 1 | 2025 | 457 | 0.190 |
Why?
|
| Pyrazines | 2 | 2018 | 94 | 0.190 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 48 | 0.190 |
Why?
|
| HCT116 Cells | 4 | 2018 | 76 | 0.190 |
Why?
|
| Ephrin-B2 | 2 | 2021 | 45 | 0.180 |
Why?
|
| Biopsy | 5 | 2023 | 1082 | 0.180 |
Why?
|
| Time Factors | 9 | 2017 | 7123 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 1 | 2024 | 152 | 0.180 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 2019 | 42 | 0.180 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 166 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2006 | 779 | 0.180 |
Why?
|
| Cell Cycle | 4 | 2018 | 598 | 0.180 |
Why?
|
| Forecasting | 1 | 2023 | 390 | 0.180 |
Why?
|
| Colic | 1 | 2001 | 10 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2023 | 44 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2025 | 969 | 0.170 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 63 | 0.170 |
Why?
|
| Tumor Burden | 5 | 2018 | 325 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 317 | 0.170 |
Why?
|
| Disease Management | 3 | 2024 | 653 | 0.170 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 428 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 886 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2021 | 118 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2025 | 399 | 0.170 |
Why?
|
| ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
|
| Tissue Distribution | 2 | 2012 | 335 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 1767 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 102 | 0.160 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2019 | 218 | 0.160 |
Why?
|
| Abdomen | 1 | 2001 | 142 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 333 | 0.160 |
Why?
|
| Momordica charantia | 1 | 2020 | 12 | 0.160 |
Why?
|
| Receptors, Enterotoxin | 2 | 2017 | 3 | 0.160 |
Why?
|
| Cell Plasticity | 1 | 2021 | 37 | 0.160 |
Why?
|
| Aurora Kinase A | 2 | 2020 | 61 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 246 | 0.160 |
Why?
|
| Topoisomerase I Inhibitors | 3 | 2017 | 19 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 325 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 118 | 0.160 |
Why?
|
| Lymphoma | 1 | 2022 | 237 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 178 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2024 | 693 | 0.150 |
Why?
|
| Half-Life | 3 | 2017 | 155 | 0.150 |
Why?
|
| Imidazoles | 2 | 2018 | 247 | 0.150 |
Why?
|
| Immune System | 1 | 2021 | 180 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 76 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 30 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2026 | 2970 | 0.150 |
Why?
|
| Disease Progression | 8 | 2025 | 2864 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 506 | 0.150 |
Why?
|
| Pancreas | 2 | 2022 | 341 | 0.150 |
Why?
|
| Benchmarking | 1 | 2020 | 191 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2017 | 178 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 106 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 588 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 337 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2016 | 25 | 0.140 |
Why?
|
| Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
|
| Melanoma | 2 | 2018 | 759 | 0.140 |
Why?
|
| Benzamides | 3 | 2014 | 226 | 0.140 |
Why?
|
| Oligopeptides | 2 | 2018 | 267 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2020 | 70 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 72 | 0.140 |
Why?
|
| CDC2 Protein Kinase | 1 | 2018 | 27 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2025 | 717 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2020 | 188 | 0.140 |
Why?
|
| United States | 10 | 2024 | 16098 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2021 | 587 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 103 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2010 | 2769 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2019 | 167 | 0.140 |
Why?
|
| Fibrosis | 1 | 2021 | 559 | 0.140 |
Why?
|
| Aminobenzoates | 1 | 2018 | 7 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 310 | 0.140 |
Why?
|
| Piperazines | 2 | 2022 | 375 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 534 | 0.130 |
Why?
|
| TWEAK Receptor | 1 | 2017 | 6 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2009 | 140 | 0.130 |
Why?
|
| Chemoradiotherapy | 4 | 2023 | 239 | 0.130 |
Why?
|
| Communication | 1 | 2024 | 975 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 3 | 2008 | 93 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2024 | 992 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2001 | 425 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 61 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 29 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2008 | 161 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 376 | 0.120 |
Why?
|
| beta Catenin | 2 | 2016 | 254 | 0.120 |
Why?
|
| Taxoids | 2 | 2008 | 114 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 107 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 50 | 0.120 |
Why?
|
| Physicians | 1 | 2025 | 955 | 0.120 |
Why?
|
| Guanylate Cyclase | 1 | 2016 | 38 | 0.120 |
Why?
|
| Niacinamide | 3 | 2012 | 104 | 0.120 |
Why?
|
| Tankyrases | 1 | 2016 | 13 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 26 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 317 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2017 | 182 | 0.120 |
Why?
|
| Gonanes | 2 | 2013 | 23 | 0.120 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 44 | 0.120 |
Why?
|
| Myenteric Plexus | 1 | 1995 | 4 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2017 | 261 | 0.110 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 31 | 0.110 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.110 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 22 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 122 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 637 | 0.110 |
Why?
|
| Fluorocarbons | 2 | 2014 | 120 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 174 | 0.110 |
Why?
|
| Gene Duplication | 1 | 2015 | 66 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 221 | 0.110 |
Why?
|
| Device Approval | 1 | 2015 | 19 | 0.110 |
Why?
|
| Retinaldehyde | 1 | 2015 | 4 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 128 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 48 | 0.110 |
Why?
|
| RNA Interference | 3 | 2016 | 475 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2025 | 8057 | 0.110 |
Why?
|
| Acetaldehyde | 1 | 2015 | 17 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2024 | 6013 | 0.110 |
Why?
|
| Young Adult | 8 | 2024 | 14219 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 165 | 0.110 |
Why?
|
| Acridines | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2024 | 2597 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 234 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2016 | 397 | 0.110 |
Why?
|
| Drug Approval | 1 | 2015 | 93 | 0.110 |
Why?
|
| Fatigue | 4 | 2012 | 364 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 153 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 892 | 0.110 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 8 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2803 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 194 | 0.100 |
Why?
|
| Piperidines | 1 | 2015 | 222 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 208 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 76 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 221 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2006 | 450 | 0.100 |
Why?
|
| Protein Binding | 2 | 2018 | 2238 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 48 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 54 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2009 | 1997 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 200 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 471 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2022 | 409 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 459 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2006 | 572 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 8 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 348 | 0.090 |
Why?
|
| Random Allocation | 1 | 2013 | 365 | 0.090 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 16 | 0.090 |
Why?
|
| Patient Selection | 3 | 2018 | 738 | 0.090 |
Why?
|
| Demography | 2 | 2010 | 282 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 86 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 91 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 148 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2019 | 1162 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 108 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2011 | 57 | 0.080 |
Why?
|
| Transplantation, Heterologous | 4 | 2016 | 170 | 0.080 |
Why?
|
| Exanthema | 2 | 2018 | 86 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2013 | 1179 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3904 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 34 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 141 | 0.080 |
Why?
|
| Organoids | 2 | 2024 | 145 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 126 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 372 | 0.080 |
Why?
|
| Estrenes | 1 | 2010 | 13 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2010 | 3413 | 0.080 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2009 | 32 | 0.080 |
Why?
|
| DNA Primers | 2 | 2009 | 505 | 0.080 |
Why?
|
| Hepatectomy | 2 | 2016 | 274 | 0.080 |
Why?
|
| Tissue Fixation | 1 | 2009 | 37 | 0.080 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 33 | 0.080 |
Why?
|
| DNA Damage | 2 | 2024 | 437 | 0.080 |
Why?
|
| Homozygote | 1 | 2010 | 199 | 0.080 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2009 | 4 | 0.070 |
Why?
|
| Formaldehyde | 1 | 2009 | 65 | 0.070 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 14 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 230 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2009 | 20 | 0.070 |
Why?
|
| Cell Separation | 1 | 2010 | 305 | 0.070 |
Why?
|
| Oximes | 2 | 2022 | 26 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2001 | 2381 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2015 | 3747 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2008 | 18 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 401 | 0.070 |
Why?
|
| Dioxoles | 1 | 2008 | 9 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2008 | 8 | 0.070 |
Why?
|
| Watchful Waiting | 2 | 2019 | 90 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 161 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2008 | 6 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 205 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 153 | 0.070 |
Why?
|
| Cytosine | 1 | 2008 | 49 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1747 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 66 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 381 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 413 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 96 | 0.060 |
Why?
|
| Colony-Stimulating Factors | 1 | 2007 | 37 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2009 | 312 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 977 | 0.060 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2008 | 89 | 0.060 |
Why?
|
| HT29 Cells | 2 | 2018 | 37 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 175 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 82 | 0.060 |
Why?
|
| Pyrroles | 2 | 2022 | 220 | 0.060 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 138 | 0.060 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 8 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 23 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 38 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2023 | 5983 | 0.060 |
Why?
|
| Gene Expression | 4 | 2019 | 1476 | 0.060 |
Why?
|
| Midazolam | 1 | 2006 | 73 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 166 | 0.060 |
Why?
|
| Estradiol | 1 | 2010 | 515 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2026 | 79 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 41 | 0.060 |
Why?
|
| Bortezomib | 1 | 2006 | 54 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2006 | 36 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 164 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 686 | 0.060 |
Why?
|
| Incidence | 2 | 2026 | 2923 | 0.060 |
Why?
|
| Microsomes, Liver | 1 | 2005 | 85 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2010 | 586 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 639 | 0.060 |
Why?
|
| Risk Factors | 5 | 2026 | 10885 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2018 | 1707 | 0.060 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 74 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 117 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 849 | 0.050 |
Why?
|
| Genotype | 1 | 2010 | 1852 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 155 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1217 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2006 | 239 | 0.050 |
Why?
|
| Anemia | 1 | 2006 | 191 | 0.050 |
Why?
|
| Rituximab | 1 | 2025 | 210 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 157 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 848 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1454 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 75 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 3342 | 0.050 |
Why?
|
| Dogs | 3 | 2010 | 458 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 69 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 162 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 555 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2158 | 0.050 |
Why?
|
| Acetonitriles | 1 | 2022 | 12 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 294 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 978 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 144 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 554 | 0.040 |
Why?
|
| G2 Phase | 2 | 2014 | 39 | 0.040 |
Why?
|
| Cisplatin | 1 | 2024 | 345 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1300 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 161 | 0.040 |
Why?
|
| Calibration | 3 | 2006 | 152 | 0.040 |
Why?
|
| Reference Standards | 3 | 2006 | 177 | 0.040 |
Why?
|
| Cell Division | 2 | 2016 | 756 | 0.040 |
Why?
|
| Medical Audit | 1 | 2001 | 77 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 118 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2001 | 176 | 0.040 |
Why?
|
| Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2022 | 125 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2023 | 385 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 562 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2021 | 77 | 0.040 |
Why?
|
| Medical Records | 1 | 2001 | 192 | 0.040 |
Why?
|
| Algorithms | 2 | 2024 | 1845 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2021 | 78 | 0.040 |
Why?
|
| Biomarkers | 3 | 2019 | 4295 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 28 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 369 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 83 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 185 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1048 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 1038 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2020 | 133 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 20 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2019 | 34 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 138 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 613 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 111 | 0.040 |
Why?
|
| Survivorship | 1 | 2019 | 57 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1044 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 184 | 0.030 |
Why?
|
| Colostomy | 1 | 2018 | 28 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 563 | 0.030 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 176 | 0.030 |
Why?
|
| Calcium | 2 | 2013 | 1190 | 0.030 |
Why?
|
| Rats | 3 | 2010 | 5584 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 204 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 2121 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 88 | 0.030 |
Why?
|
| Adolescent | 3 | 2024 | 22530 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 14 | 0.030 |
Why?
|
| Anal Canal | 1 | 2018 | 102 | 0.030 |
Why?
|
| Adenine | 1 | 2020 | 339 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 910 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 18 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 21 | 0.030 |
Why?
|
| Education | 1 | 2017 | 104 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 79 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 500 | 0.030 |
Why?
|
| fas Receptor | 1 | 1997 | 91 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 442 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 182 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 55 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2016 | 29 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
|
| Axin Protein | 1 | 2016 | 18 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 142 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 959 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 104 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 105 | 0.030 |
Why?
|
| Leadership | 1 | 2020 | 401 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 49 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 51 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 116 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Flavin Mononucleotide | 1 | 1995 | 7 | 0.030 |
Why?
|
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 1995 | 4 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1995 | 8 | 0.030 |
Why?
|
| Palliative Care | 1 | 2024 | 1020 | 0.030 |
Why?
|
| Polymyositis | 1 | 1995 | 13 | 0.030 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 1995 | 15 | 0.030 |
Why?
|
| NADP | 1 | 1995 | 52 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 665 | 0.030 |
Why?
|
| Dermatomyositis | 1 | 1995 | 24 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 70 | 0.030 |
Why?
|
| History, Ancient | 1 | 2015 | 53 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1508 | 0.030 |
Why?
|
| Diphenylamine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Citrulline | 1 | 1995 | 45 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1995 | 100 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 200 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 377 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 699 | 0.030 |
Why?
|
| Myositis | 1 | 1995 | 57 | 0.030 |
Why?
|
| Rhodamines | 1 | 2014 | 19 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 267 | 0.030 |
Why?
|
| Oxaloacetates | 1 | 2014 | 2 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 112 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 62 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 450 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 442 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 93 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 125 | 0.030 |
Why?
|
| Histones | 2 | 2010 | 666 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 825 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 264 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1327 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3124 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1547 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 926 | 0.020 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 2930 | 0.020 |
Why?
|
| Neutrophils | 1 | 2019 | 1124 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 558 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 63 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1997 | 468 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 847 | 0.020 |
Why?
|
| Receptors, CXCR | 1 | 2012 | 5 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 919 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 3155 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2018 | 696 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 64 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 6066 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2014 | 396 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 527 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 2134 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 456 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2012 | 62 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 112 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1038 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 94 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2013 | 131 | 0.020 |
Why?
|
| Antioxidants | 1 | 1995 | 550 | 0.020 |
Why?
|
| Vomiting | 1 | 2012 | 131 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1997 | 489 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1490 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 245 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 1764 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 28 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 167 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 674 | 0.020 |
Why?
|
| Thalidomide | 1 | 2010 | 43 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 204 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 4106 | 0.020 |
Why?
|
| Paxillin | 1 | 2009 | 11 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 249 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1598 | 0.020 |
Why?
|
| Infliximab | 1 | 2009 | 111 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 1996 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1891 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 546 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2008 | 104 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 669 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 507 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 335 | 0.020 |
Why?
|
| Staurosporine | 1 | 2007 | 22 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 259 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 307 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 154 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 27 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 487 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 42 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 61 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hepatic Artery | 1 | 2006 | 53 | 0.020 |
Why?
|
| Leukocytes | 1 | 2008 | 296 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 116 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2006 | 180 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 170 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 70 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 574 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 69 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 239 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2009 | 776 | 0.010 |
Why?
|
| Ritonavir | 1 | 2005 | 75 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 387 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 486 | 0.010 |
Why?
|
| Tubulin | 1 | 2005 | 146 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 2953 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 592 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 1111 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2008 | 972 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1567 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 497 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2823 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 730 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 1273 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1997 | 21 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1997 | 27 | 0.010 |
Why?
|
| Myelin Basic Protein | 1 | 1997 | 44 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 263 | 0.010 |
Why?
|
| Cell Death | 1 | 1997 | 382 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 334 | 0.010 |
Why?
|
| Multigene Family | 1 | 1995 | 210 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 362 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 427 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2170 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2129 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 2883 | 0.010 |
Why?
|